Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Menu
Stocks | Futures | Watchlist | More
 
No Matching Results
Advanced search
or
Site News
Market: Market:

Chromadex Corp CS (CDXC)

Chromadex Corp CS (CDXC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alerts
Watch
Help
Go To:
ChromaDex to Present at American Society for Nutrition (ASN), International Society of Sports Nutrition (ISSN), and Federation of American Societies for Experimental Biology (FASEB) Business Wire - Wed Jun 15, 5:34AM CDT

ChromaDex Corp. (NASDAQ:CDXC) today announced that members of its team, a Scientific Advisory Board member and two ChromaDex External Research Program (CERP™) investigators, will be presenting at several...

CDXC : 1.7400 (+4.19%)
ChromaDex Signs Sinopharm Xingsha Agreement to Accelerate Cross-Border Sales of Tru Niagen® into Mainland China Business Wire - Fri Jun 10, 5:32AM CDT

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, today announced a signed distribution agreement with Sinopharm Xingsha to accelerate cross-border...

CDXC : 1.7400 (+4.19%)
ChromaDex to Present at the Oppenheimer’s 22nd Annual Consumer Growth and E-Commerce Conference Business Wire - Tue Jun 7, 12:33PM CDT

ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting at Oppenheimer’s 22 nd Annual Consumer Growth and...

CDXC : 1.7400 (+4.19%)
ChromaDex Partners with Juvenis for Cross-Border Sales of Tru Niagen® into South Korea Business Wire - Thu Jun 2, 5:34AM CDT

ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with Juvenis to conduct cross-border sales of Tru Niagen ® in South Korea. Juvenis is a Korean healthcare marketing company with a focus on...

CDXC : 1.7400 (+4.19%)
ChromaDex to Present at the LD Micro Invitational Business Wire - Wed Jun 1, 5:32AM CDT

ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the 12 th annual Invitational. This...

CDXC : 1.7400 (+4.19%)
ChromaDex Announces Agreement to Launch Commercial Joint Venture in Mainland China Business Wire - Thu May 19, 3:34PM CDT

ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, today announced it has entered into an agreement (the “JV Agreement”) to establish a joint...

CDXC : 1.7400 (+4.19%)
ChromaDex Wins International 2022 European NutraIngredients Award for Developing the Science Behind Niagen® Business Wire - Tue May 17, 5:34AM CDT

ChromaDex Corp. (NASDAQ:CDXC) announced today that NutraIngredients , a leading news source for the nutrition industry, recently honored the ChromaDex External Research Program (CERP TM ) with a 2022...

CDXC : 1.7400 (+4.19%)
ChromaDex (CDXC) Reports Q1 Loss, Misses Revenue Estimates Zacks - Thu May 12, 4:35PM CDT

ChromaDex (CDXC) delivered earnings and revenue surprises of -22.22% and 0.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CDXC : 1.7400 (+4.19%)
BIOVF : 21.9225 (-1.56%)
ChromaDex Corporation Reports First Quarter 2022 Financial Results Business Wire - Thu May 12, 3:03PM CDT

ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2022.

CDXC : 1.7400 (+4.19%)
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates Zacks - Mon May 9, 7:25AM CDT

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 52.63% and 55.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ADCT : 8.63 (+1.05%)
CDXC : 1.7400 (+4.19%)

Barchart Exclusives

Barchart Releases Initial Canadian Crop Production and Yield Forecasts Below AAFC Estimates Barchart - 55 minutes ago
Today, Barchart released its initial July 2022 Yield and Production forecasts for Canadian Spring Wheat and Soybeans, which predicts yield below the AAFC's most recent forecast. Barchart's forecast for Candian spring wheat production is 907.7B bu with an end-of-season yield of 52.6 (bu/ac). Barchart’s spring wheat yield forecast is 1.5... Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' : 'America/Chicago' ]] CDT
Reserve Your Spot